Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Therapeutic suppression of translation initiation modulates chemosensitivity in a mouse lymphoma model
Marie-Eve Bordeleau, Francis Robert, Baudouin Gerard, Lisa Lindqvist, Samuel M.H. Chen, Hans-Guido Wendel, Brigitte Brem, Harald Greger, Scott W. Lowe, John A. Porco Jr., Jerry Pelletier
Marie-Eve Bordeleau, Francis Robert, Baudouin Gerard, Lisa Lindqvist, Samuel M.H. Chen, Hans-Guido Wendel, Brigitte Brem, Harald Greger, Scott W. Lowe, John A. Porco Jr., Jerry Pelletier
View: Text | PDF
Research Article Oncology

Therapeutic suppression of translation initiation modulates chemosensitivity in a mouse lymphoma model

  • Text
  • PDF
Abstract

Disablement of cell death programs in cancer cells contributes to drug resistance and in some cases has been associated with altered translational control. As eukaryotic translation initiation factor 4E (eIF4E) cooperates with c-Myc during lymphomagenesis, induces drug resistance, and is a genetic modifier of the rapamycin response, we have investigated the effect of dysregulation of the ribosome recruitment phase of translation initiation on tumor progression and chemosensitivity. eIF4E is a subunit of eIF4F, a complex that stimulates ribosome recruitment during translation initiation by delivering the DEAD-box RNA helicase eIF4A to the 5′ end of mRNAs. eIF4A is thought to prepare a ribosome landing pad on mRNA templates for incoming 40S ribosomes (and associated factors). Using small molecule screening, we found that cyclopenta[b]benzofuran flavaglines, a class of natural products, modulate eIF4A activity and inhibit translation initiation. One member of this class of compounds, silvestrol, was able to enhance chemosensitivity in a mouse lymphoma model in which carcinogenesis is driven by phosphatase and tensin homolog (PTEN) inactivation or elevated eIF4E levels. These results establish that targeting translation initiation can restore drug sensitivity in vivo and provide an approach to modulating chemosensitivity.

Authors

Marie-Eve Bordeleau, Francis Robert, Baudouin Gerard, Lisa Lindqvist, Samuel M.H. Chen, Hans-Guido Wendel, Brigitte Brem, Harald Greger, Scott W. Lowe, John A. Porco Jr., Jerry Pelletier

×

Figure 3

Effects of CBFs on protein, RNA, and DNA synthesis in vivo.

Options: View larger image (or click on image) Download as PowerPoint
Effects of CBFs on protein, RNA, and DNA synthesis in vivo.
(A) Dose-dep...
(A) Dose-dependent inhibition of protein synthesis in vivo by CBFs. HeLa cells were incubated with the indicated concentrations of FA and silvestrol for 1 hour, with [35S]methionine added 10 minutes before the end of the incubation. The rate of [35S]methionine (35S]-Met) incorporation is expressed relative to that of cells treated with vehicle (MeOH). Results are expressed as mean ± SEM of 2 experiments. (B) CBFs primarily impact protein synthesis in vivo. HeLa cells were incubated with 5 μM FA, 0.4 μM silvestrol, or vehicle (MeOH) for 1 hour. The rate of incorporation of each radioisotope tracer into TCA-insoluble material is expressed relative to that in MeOH-treated cells. Results are expressed as mean ± SEM of 2 experiments. (C) Inhibition of translation by CBFs is reversible. HeLa cells were incubated for 1 hour with 10 μM anisomycin, 5 μM FA, 0.4 μM silvestrol, or MeOH. Cells were then washed with PBS and incubated with medium lacking compound for the indicated times. Ten minutes before harvesting, [35S]methionine was added to the culture. The rate of [35S]methionine incorporation into TCA-insoluble material is expressed relative to that in MeOH-treated cells. Results are expressed as mean ± SEM of 3 experiments. Anisomycin acts a positive control, since recovery of protein synthesis from inhibition with this compound occurs within an hour of its removal from cells (65). (D) CBFs inhibit cap-dependent translation in vivo. Top: Schematic representation of pcDNA/Ren/HCV/FF expression vector. Bottom: Effect of FA on cap-dependent and HCV IRES–mediated translation in 293 cells transfected with pcDNA/Ren/HCV/FF. Luciferase activity is expressed relative to that in MeOH-treated cells and is the mean ± SEM of 2 experiments. (E) Silvestrol does not induce eIF2α phosphorylation. HeLa cells were incubated for 2 hours in the presence of vehicle (DMSO), thapsigargin (2 μg/ml), or silvestrol (400 nM), after which extracts were analyzed by Western blotting. (F) Silvestrol induces apoptosis at concentrations higher than those required to inhibit protein synthesis. Jurkat cells were incubated with the indicated silvestrol concentrations for 13 hours, after which the rate of [35S]methionine incorporation or the percentage of living cells was measured. Results are expressed as mean ± SEM of 2 experiments.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts